1. Home
  2. AGIO vs PRG Comparison

AGIO vs PRG Comparison

Compare AGIO & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$30.08

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$29.37

Market Cap

1.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
PRG
Founded
2007
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
AGIO
PRG
Price
$30.08
$29.37
Analyst Decision
Buy
Buy
Analyst Count
8
7
Target Price
$37.63
$47.50
AVG Volume (30 Days)
623.7K
463.7K
Earning Date
04-30-2026
04-22-2026
Dividend Yield
N/A
1.81%
EPS Growth
N/A
N/A
EPS
N/A
3.59
Revenue
$43,011,000.00
$2,409,223,000.00
Revenue This Year
$71.05
$25.27
Revenue Next Year
$163.65
$6.59
P/E Ratio
N/A
$8.00
Revenue Growth
N/A
N/A
52 Week Low
$22.24
$23.50
52 Week High
$46.00
$41.14

Technical Indicators

Market Signals
Indicator
AGIO
PRG
Relative Strength Index (RSI) 62.40 41.32
Support Level $26.48 $27.63
Resistance Level $30.90 $30.68
Average True Range (ATR) 0.97 1.12
MACD 0.10 -0.14
Stochastic Oscillator 98.65 33.09

Price Performance

Historical Comparison
AGIO
PRG

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

Share on Social Networks: